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plasma cell‑free DnA methylation 
marks for episodic memory 
impairment: a pilot twin study
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R. Lahesmaa1, J. Kaprio5,6, J. O. Rinne4 & R. J. Lund1
Decline in episodic memory performance usually causes the first clinical symptoms of Alzheimer’s 
disease. At present, Alzheimer’s disease can only be diagnosed at a very late stage when 
neurodegeneration and cognitive impairment is already irreversible. New early disease markers 
are needed for earlier and more efficient Alzheimer’s disease intervention. To identify early disease 
markers, we implemented a genome-wide bisulphite sequencing method for the analysis of plasma 
cell-free DNA methylation profiles and compared differences associated with episodic memory 
performance in Finnish twin pairs. A noticeable amount of cell-free DNA was present in plasma, 
however, the amounts as well as the genomic coverage of these fragments varied substantially 
between individuals. We found no significant markers associated with episodic memory performance 
in the twins’ plasma cell-free DNA methylation profiles. Furthermore, our results indicate that 
due to the low genomic coverage of cell-free DNA fragments and the variety in these fragments 
between individuals, the implemented genome-wide bisulphite sequencing method is not optimal for 
comparing cell-free DNA methylation differences between large groups of individuals.
Episodic memory (EM) is the memory type that starts to decline early in Alzheimer’s disease (AD) causing 
the usual first symptoms of dementia, like problems in remembering recent events and setting these events to 
the timeline. Alzheimer’s disease is the most common cause of dementia, inflicting tens of millions of patients 
 worldwide1. Currently, AD can be clinically diagnosed only at a very late stage when neurodegeneration is far-
progressed and patients’ cognitive impairment is already irreversible. While the initial triggers for AD are not 
completely known, the disease progression may start already 20–30 years before it can be  diagnosed2. New early 
diagnostic or prognostic markers would be valuable enabling early intervention studies and evaluation of their 
effectiveness prior to the stage when severe neuronal damage has occurred in the disease process. Others and 
we have previously identified DNA methylation marks associated with AD or dementia in specific brain regions 
and in peripheral whole  blood3–5. Plasma circulating cell-free DNA (cfDNA) methylation marks have emerged as 
a potential method for monitoring of cancers, rejection of organ transplantation and in prenatal  diagnostics6–8. 
Whether these marks could be utilized to detect dementia is not clear. As cfDNA has been detected to leak 
into plasma from dying cells in cancers, cfDNA could be leaking to the blood circulation from the degenerat-
ing neuronal cells as  well9. In this pilot study, our goal was to test and optimize the method for plasma cfDNA 
methylation sequencing and determine whether cfDNA methylation marks associated with EM performance 
can be detected in Finnish twin study participants.
Results
Optimization of the sample preparation method for cell-free DNA methylome analysis. To 
optimize the sample preparation method for cfDNA methylome analysis, we first examined the impact of anti-
coagulant type on the cfDNA yields. For this purpose, whole blood was collected into EDTA (n = 3) and CPT 
(n = 4) tubes. Plasma was fractionated and cfDNAs were isolated from each sample by using 1,000 μl volume 
of plasma. The cfDNA yields varied between 2.05 and 17.08  ng. No statistically significant differences were 
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detected in the cfDNA yields between EDTA or CPT plasma (paired t-test p-value 0.20, Supplementary Fig. S1). 
We then examined impact of plasma volume on the cfDNA yields. For this purpose, cfDNAs were isolated from 
1,000, 750 and 500 μl of EDTA plasma with Qiagen QIAamp Circulating Nucleic Acid kit that is optimized for 
up to 5 ml plasma volumes. When using 500 μl of EDTA plasma as a starting volume, two of three replicates 
did not yield any cfDNA indicating that this starting volume is not robust for cfDNA isolation. When using 750 
and 1,000 ul of EDTA plasma cfDNAs were successfully isolated from all samples. There were no differences 
(t-test p-value > 0.20) in the cfDNA yields between different starting volumes of plasma (Supplementary Fig. S1), 
although, there was more variation in the isolated cfDNA yields with the lower plasma volumes. Our results 
indicated that further increase in the plasma volume would not increase the yield.
Next, we determined whether bisulphite sequencing libraries can be prepared from these samples and whether 
the type of the anticoagulant and starting amount of cfDNA affect the number of detected CpG sites. Library 
preparation from all the samples was successful. The libraries were prepared from 2.0–10 ng of cfDNA isolated 
from EDTA plasma and 1.0–17 ng of cDNA isolated from CPT plasma. According to the results, there were no 
differences in the number of CpG sites detected in samples prepared from EDTA plasma when compared to the 
CPT plasma (t-test p-value 0.7). Furthermore, the correlation between the number of detected CpG sites and 
the amount of cfDNA used as starting material for library preparation was not statistically significant (Pearson’s 
correlation 0.28, p-value 0.44, Supplementary Fig. S2).
pilot analysis of plasma cfDnA markers associated with episodic memory performance in 
finnish twin pairs. To identify plasma cell-free markers for EM performance, we then repeated the analysis 
by using samples collected from Finnish twin cohort. Our first null hypothesis was that the plasma cell-free 
DNA yields do not correlate with the EM performance. To test this hypothesis, cell-free DNAs were isolated 
from 1 ml of plasma collected from seven Finnish twin pairs (see materials and methods section for details). Of 
these twin pairs four were discordant for EM impairment, two pairs were cognitively preserved and in one pair 
both siblings were affected (Table 1). The cfDNA yields from the 14 individuals varied between 3.9 and 30.90 ng, 
however, did not correlate with the Logical Memory delayed recall (r = − 0.16, p = 0.58) or delayed word list recall 
(r = − 0.17, p = 0.57) scores. Therefore, the null hypothesis was not rejected.
Our second null hypothesis was that cell-free DNA methylation marks associated with EM performance 
cannot be detected in plasma. To test this hypothesis, we characterised plasma cfDNA methylomes of the seven 
twin pairs (14 individuals) with whole genome bisulphite sequencing and analysed whether plasma cfDNA 
methylation is associated with EM performance. The number of CpG sites detected in each individual with 
10 × sequencing coverage varied between 4,023 and 13,414. A total number of 2,089 CpG sites were detected in all 
14 individuals with 10 × sequencing coverage and were included in the differential methylation analysis (Fig. 1). 
Of these sites 99.52% were located in intergenic regions of the genome. Differential methylation was analysed 
using a binomial mixed model implemented in R package  PQLseq10. The EM z-score was set as the test variable, 
gender, age, zygosity and APOE genotype were included as fixed effects and twin pair ID was included as random 
effect in the model. APOE genotype was added as a fixed effect variable since it is a significant risk factor for AD 
and our previous results indicate that it can correlate with DNA methylation in peripheral  blood3. The model 
converged in 2002 of the 2089 CpG sites. To control for multiple testing, p-values were adjusted by combining 
the significance levels of nearby CpG sites, using  RADMeth11, and corrected using FDR. After correction, we 
detected no significant methylation differences associated with EM performance (adjusted FDR < 0.05) (Fig. 2, 
Supplementary Table S1). Therefore, we did not reject the null hypothesis. 
Table 1.  Description of the seven Finnish twin pairs included in the plasma cell-free DNA methylation 
analysis. Their mean age was 74.1 years (range 73–76). Zygosity (1: monozygotic, 2: dizygotic), EM episodic 
memory.
Twin pair ID Zygosity Gender EM status EM z-score APOE genotype Amount of DNA isolated (ng)
MZ1 1 Male Impaired − 1.75 33 4.9
MZ1 1 Male Impaired − 2.67 33 7.5
MZ2 1 Male Normal 1.23 33 10.7
MZ2 1 Male Normal − 0.11 33 11.6
DZ1 2 Female Impaired − 1.19 33 30.9
DZ1 2 Female Normal 0.56 33 6.8
DZ2 2 Male Normal − 0.52 33 8.7
DZ2 2 Male Normal − 0.52 33 5.6
DZ3 2 Male Normal 0.30 34 5.5
DZ3 2 Male Impaired − 3.08 34 19.5
DZ4 2 Female Normal 0.59 33 11.4
DZ4 2 Female Impaired − 2.80 34 8.0
DZ5 2 Female Impaired − 2.13 44 3.9
DZ5 2 Female Normal 1.12 34 5.4
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As a conclusion, no differentially methylated sites associated with EM performance were detected in plasma 
circulating cfDNA with our sample size and analysis methods.
Discussion
In this study, we implemented a method for whole genome bisulphite sequencing of plasma cfDNA. The method 
was piloted by comparing plasma cfDNA methylation differences associated with EM performance in Finnish 
twin pairs. To our knowledge, there is no previous published studies on genome-wide characterisation of plasma 
Figure 1.  CpG sites detected with plasma cell-free DNA bisulphite sequencing. (a) CpG sites detected 
with ≥ 10 × sequencing coverage in one or more twin study participants. (b) CpG sites detected 
with ≥ 10 × sequencing coverage in all of the twin participants. The CpG sites in figure (b) were included in the 
differential methylation analysis. Color scaling: number of sites detected within one million base pair windows.
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cfDNA methylation markers for EM impairment even though several groups have identified DNA methylation 
differences associated with neurodegenerative diseases in brain tissue and peripheral  blood3–5. However, plasma 
cell-free DNA methylation markers have been characterized for other human diseases, like cancers, and biological 
conditions, like prenatal diagnostics and organ transplant monitoring using similar sequencing-based methods 
as well as methylation  arrays6–8. In addition, a recent study that utilised targeted bisulphite pyrosequencing 
reported neuronal tissue specific methylation pattern in LIM homeobox 2 (LHX2) gene in plasma cfDNA asso-
ciated with  AD12.
The cfDNA amounts, isolated from 1 ml twin plasma samples varied from less than four nanograms to more 
than thirty nanograms. Our results suggest that there is noticeable amount of cfDNA circulating in peripheral 
blood, however, the amount may vary a lot between individuals. Furthermore, plasma cfDNA amounts did not 
correlate with EM performance, in contrast to the findings Pai and his group discovered in their  study12. However, 
Pai’s group quantified circulating cfDNA in AD patients who have more severe neurodegeneration and cognitive 
impairment than our study participants. Thus, it is possible that plasma cfDNA levels increase as neurodegenera-
tion progresses further. We detected between 4,023 and 13,414 CpG sites with 10 × sequencing coverage in each 
twin sample, which indicates that also the genomic coverage of the cfDNA fragments varies substantially between 
individuals and therefore the method is not optimal to compare large groups of individuals. A vast majority of 
the detected sites located in the intergenic regions of the genome, especially in centromeres and telomeres, which 
suggests that these functional genomic regions are highly represented in plasma cfDNA. We did not detect any 
significant differences in methylation of the cfDNA fragments associated with EM impairment. Since our study 
material consisted of samples from individuals with relatively mild cognitive deficits, it is possible that DNA 
methylation markers would be detectable at a later stage when neurodegeneration is more severely progressed.
The low number of twin pairs that we were able to obtain for this study was a limitation in the pilot analysis 
of plasma cell-free DNA methylation differences associated with EM performance. However, we detected no 
promising marker candidates and our results indicate that both cfDNA amounts and genomic coverage of these 
fragments vary remarkably between individuals. After all, only 2,089 of the 28 million CpG sites in human 
genome were detected in all of our study participants with sufficient sequencing coverage. Thus, we think that 
no reliable methylation marks associated with mild EM impairment can be identified in plasma cfDNA with 
the implemented genome-wide bisulphite sequencing method that we applied even if the number of twin pairs 
could be increased.
Materials and methods
Description of the study participants. A total number of 559 same-sex twin pairs (born 1938–1944) 
from the older Finnish Twin Cohort participated in a telephone-based cognitive screening. According to pri-
mary information about their cognitive performance 45 individuals; nine monozygotic twin pairs and nine 
dizygotic twin pairs as well as eight non-twin controls, were invited for further assessment at the Turku PET 
Centre, Finland, where they underwent blood sampling and neurophysiological testing in 2014–201713–15. From 
the 18 twin pairs we selected the seven first ones with plasma sample available at the time of the study; two 
Figure 2.  Methylation differences associated with episodic memory performance in the Finnish twins. The 
manhattan plots show multiple test corrected log10(p)-values in the outer circle and unadjusted log10(p)-values 
in the inner circle for CpG sites that were included in the analysis. Generalised linear mixed effects model 
(PQLseq) was utilised to test for plasma cfDNA methylation marks associated with EM performance within the 
seven twin pair sample set.
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monozygotic and five dizygotic twin pairs, who were examined at PET Centre before July 2016, for a cell-free 
DNA methylation characterization pilot (Table 1). The participants were administered a neuropsychological test 
battery that included the delayed word list recall from the Consortium to Establish a Registry for Alzheimer’s 
disease Neuropsychological Battery (CERAD-NB) and Logical Memory delayed recall from the Wechsler Mem-
ory Scale-Revised (WMS-R). The test performances were transformed into standard deviation (SD) units based 
on age-appropriate Finnish  norms16,17. Following the Jak/Bondi neuropsychological criteria, participants were 
defined to have EM impairment if they had ≤ − 1 SD or poorer performance in both delayed verbal recall  tests18. 
According to these criteria, four twin pairs were discordant for EM impairment (Table 1). The EM z-score values 
in Table 1 are the combined means from CERAD-NB and WMS-R test scores. In addition to the twin samples, 
we collected test plasma samples into EDTA and CPT tubes from eight non-related controls in total for testing 
and optimizing the sample preparation protocol. (Supplementary Table S2).
The study was approved by the Ethics Committee of Hospital District of Southwest Finland. The study was 
conducted according to good clinical and scientific practices and following the ethical principles of the Declara-
tion of Helsinki. Informed consent was obtained from all study participants.
DnA isolation. DNA was isolated from plasma with Qiagen’s QIAamp Circulating Nucleic Acids kit. For 
library preparation testing DNA was isolated from 500 µl, 750 µl or 1,000 µl of plasma. Plasma was extracted 
from EDTA or CPT blood samples within two hours after sampling, snap-frozen in dry ice and stored in −80 °C 
before DNA isolation. Twin samples were stored in CPT tubes and 1,000 µl of plasma was used in DNA isolation 
per sample. Isolated DNA quality was analysed with Agilent Bioanalyzer 2100 High-Sensitivity DNA assay and 
DNA was quantified with Invitrogen Qubit 2.0 dsDNA HS assay.
Library preparation. Bisulphite sequencing library preparation test was started with 2 to 10 ng of plasma 
DNA per sample. Library preparation conditions for the test samples can be seen in more detail in Supple-
mentary Table S2. Library preparation started with end-filling/A-tailing reaction with Klenow fragment (New 
England Biolabs) and nucleotide mix containing 10 × concentration of ATP compared to other nucleotides, and 
unmethylated lambda DNA. The reaction mix was incubated 30 min in 30 °C and 30 min in 37 °C. In the next 
step Illumina TruSeq sequencing adapters were ligated to the DNA fragments with T4 DNA ligase (New Eng-
land Biolabs) and overnight incubation in 16 °C. After adapter ligation, libraries were purified with AMPure XP 
beads in 2.5X bead concentration. Bisulphite conversion was carried out with Invitrogen MethylCode Bisulfite 
Conversion kit, according to the manufacturer’s instructions. 25 ng of carrier DNA (sheared E. Coli DNA) was 
added to each library sample before conversion. Libraries were amplified in an 18 cycle PCR and purified two 
times with AMPure XP beads, 1.2X and 1.5X bead concentration. Library concentrations were measured with 
Qubit 2.0 HS DNA assay and quality analysed with Bioanalyzer 2,100 High Sensitivity DNA assay. The twin 
sample bisulphite sequencing libraries were prepared from 3 ng of plasma DNA.
Sequencing and data analysis. Libraries were sequenced with Illumina HiSeq 2500/3000 1 × 50 bp chem-
istry. The trimmed reads (Trim Galore 0.4.119) were mapped to hg38 reference genome with Bismark 0.14.520. 
Centromere regions, haplotype and sex chromosomes and repetitive regions that had very high sequencing 
coverage were filtered out from the data set. Differential methylation was tested at individual CpG sites with 
 PQLseq10 (version 1.1) software. PQLseq was utilised to identify plasma cfDNA methylation markers associated 
with EM performance in the whole seven twin pair sample set. PQLseq implements a generalised linear mixed 
effects model to test for differential methylation associated with a given trait. All seven pairs (14 twins) were 
included in the mixed model analysis, however, only CpG sites that were detected with at least 10 × sequenc-
ing coverage in all individuals were included. 10 × sequencing coverage means that a CpG site is covered by ten 
unique sequencing reads after mapping, i.e. the site is sequenced ten times in the library sample. EM z-score 
was set as the predictor variable. Gender, age, twin zygosity and APOE genotype were included as fixed effects 
and twin pair ID as a random effect in the model. The p-values obtained from PQLseq analysis were adjusted by 
combining the p-values of nearby CpG sites and FDR corrected for multiple testing using methPipe/RADMeth 
(version 3.4.3)11. The threshold for differential methylation was adjusted FDR < 0.05.
 Data availability
All the data supporting the findings in this study are available within the article or upon request from the cor-
responding author.
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